scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1091101507 |
P356 | DOI | 10.1007/S10549-017-4430-2 |
P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s10549-017-4430-2 |
P932 | PMC publication ID | 5669824 |
P698 | PubMed publication ID | 28791495 |
P50 | author | Yiwey Shieh | Q81345889 |
Karla Kerlikowske | Q92299671 | ||
P2093 | author name string | Lin Ma | |
Elad Ziv | |||
Steven R Cummings | |||
Jeffrey A Tice | |||
Donglei Hu | |||
Scott Huntsman | |||
Charlotte C Gard | |||
Jessica W T Leung | |||
P2860 | cites work | Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk | Q28390064 |
Large-scale genotyping identifies 41 new loci associated with breast cancer risk | Q29416989 | ||
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status | Q30665329 | ||
Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study | Q33891825 | ||
Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials | Q34039907 | ||
Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer | Q34225990 | ||
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force | Q34339445 | ||
Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. | Q34372923 | ||
Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers | Q34764884 | ||
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline | Q34802964 | ||
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies | Q35287715 | ||
Dense and nondense mammographic area and risk of breast cancer by age and tumor characteristics | Q35562818 | ||
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | Q35996692 | ||
Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer | Q36090967 | ||
The contributions of breast density and common genetic variation to breast cancer risk | Q36137764 | ||
Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry | Q36619329 | ||
Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study | Q36673712 | ||
Testing for improvement in prediction model performance. | Q36763246 | ||
Misuse of DeLong test to compare AUCs for nested models | Q36933642 | ||
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model | Q37172219 | ||
Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials | Q37351543 | ||
Mammographic density and risk of breast cancer by age and tumor characteristics | Q37690341 | ||
Obesity and the risk for premenopausal and postmenopausal breast cancer | Q37990775 | ||
Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study | Q38442766 | ||
Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer | Q39045823 | ||
Breast cancer risk prediction using a clinical risk model and polygenic risk score | Q40605693 | ||
Circulating steroid hormone levels and risk of breast cancer for postmenopausal women | Q43189592 | ||
Serum estradiol level and risk of breast cancer during treatment with raloxifene | Q43846631 | ||
Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies | Q43963634 | ||
Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women | Q45188730 | ||
Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). | Q46116676 | ||
A breast cancer prediction model incorporating familial and personal risk factors. | Q52000310 | ||
Should We Offer Medication to Reduce Breast Cancer Risk?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. | Q53585593 | ||
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually | Q69396132 | ||
Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women | Q79182457 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | estrogen-receptor positive breast cancer | Q18553636 |
P304 | page(s) | 603-612 | |
P577 | publication date | 2017-08-08 | |
P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
P1476 | title | Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones | |
P478 | volume | 166 |
Q57748350 | Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control study |
Q93169632 | Breast cancer chemoprevention: An update on current practice and opportunities for primary care physicians |
Q89746441 | Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field |
Q64279327 | Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk |
Q57074024 | Women's preferences, willingness-to-pay, and predicted uptake for single-nucleotide polymorphism gene testing to guide personalized breast cancer screening strategies: a discrete choice experiment |
Search more.